What I am working with: GGT · four weeks · dulaglutide.
I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.
I want to know whether this is recoverable or whether the honest answer is to write it off.
How do I distinguish the benign explanation from the one that matters?
4 weeks is 28 days, and the first question about any marker is whether 28 days is long enough for it to have finished moving. GGT turns over slowly, over two to three weeks, and responds to hepatic fat and to alcohol with roughly equal enthusiasm. Against 28 days the marker is at or near the edge of its own settling time, so part of what you are reading is the transition rather than the destination. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 28 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.
The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStandardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
The part that matters: delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Keep the full report, not the number. You will need the units and the interval later.
edited 10 Nov 2024 by Dr_Bram_Verhoeven — added the method parameters
In practice, this is answerable, and the answer is mostly about which tests rather than how many.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Decide the action for each result before you order the test.
The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Research-use compounds are not approved for human use, and no panel makes that safer.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.